New Zealand markets open in 5 hours 1 minute

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
40.97-0.37 (-0.90%)
As of 10:59AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close41.34
Bid41.55 x 800
Ask41.55 x 1200
Day's range40.85 - 41.95
52-week range34.86 - 53.23
Avg. volume2,395,547
Market cap17.597B
Beta (5Y monthly)N/A
PE ratio (TTM)21.27
EPS (TTM)1.93
Earnings date15 Feb 2022 - 21 Feb 2022
Forward dividend & yield0.68 (1.64%)
Ex-dividend date18 Nov 2021
1y target est51.43
  • GlobeNewswire

    Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

    NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is

  • GlobeNewswire

    Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

    Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closi

  • GlobeNewswire

    Royalty Pharma Reports Third Quarter 2021 Results

    Net cash provided from operating activities (GAAP) of $470 million; Adjusted Cash Receipts(1) (non-GAAP) of $587 million and Adjusted Cash Flow(2) (non-GAAP) of $441 millionAnnounced transactions of up to $2.8 billion in 2021, including $2.1 billion in upfront paymentsRaises 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,110 to $2,130 million NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 an